Trade Aldeyra Therapeutics, Inc. - ALDX CFD

Add to favourite

3.84

3.03%

0.05

Low: 3.77

High: 3.96

Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.05

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Aldeyra Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	3.96
Open*	3.94
1-Year Change*	-62.15%
Day's Range*	3.77 - 3.96
52 wk Range	1.42-11.97
Average Volume (10 days)	558.07K
Average Volume (3 months)	53.26M
Market Cap	178.82M
P/E Ratio	-100.00K
Shares Outstanding	58.82M
Revenue	N/A
EPS	-0.78
Dividend (Yield %)	N/A
Beta	1.50
Next Earnings Date	Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	3.96	0.06	1.54%	3.90	4.05	3.87
Apr 17, 2024	3.95	0.11	2.86%	3.84	4.12	3.79
Apr 16, 2024	3.85	-0.19	-4.70%	4.04	4.06	3.82
Apr 15, 2024	4.14	-0.02	-0.48%	4.16	4.29	4.03
Apr 12, 2024	4.23	-0.12	-2.76%	4.35	4.44	4.17
Apr 11, 2024	4.37	0.16	3.80%	4.21	4.45	4.18
Apr 10, 2024	4.22	-0.02	-0.47%	4.24	4.26	4.07
Apr 9, 2024	4.40	-0.14	-3.08%	4.54	4.65	4.31
Apr 8, 2024	4.35	-0.54	-11.04%	4.89	4.89	4.27
Apr 5, 2024	4.69	0.05	1.08%	4.64	4.90	4.56
Apr 4, 2024	4.66	0.14	3.10%	4.52	4.85	4.37
Apr 3, 2024	4.13	0.51	14.09%	3.62	4.19	3.60
Apr 2, 2024	3.53	0.31	9.63%	3.22	3.54	3.17
Apr 1, 2024	3.25	-0.03	-0.91%	3.28	3.31	3.10
Mar 28, 2024	3.24	0.13	4.18%	3.11	3.48	3.11
Mar 27, 2024	3.07	0.16	5.50%	2.91	3.11	2.86
Mar 26, 2024	2.90	0.01	0.35%	2.89	2.94	2.87
Mar 25, 2024	2.86	-0.04	-1.38%	2.90	2.97	2.83
Mar 22, 2024	2.88	-0.02	-0.69%	2.90	2.92	2.85
Mar 21, 2024	2.88	-0.04	-1.37%	2.92	3.01	2.88

Aldeyra Therapeutics, Inc. Events

Time (UTC)	Country	Event
Thursday, May 2, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Aldeyra Therapeutics Inc Earnings Release Q1 2024 Aldeyra Therapeutics Inc Earnings Release Forecast - Previous -
Friday, June 28, 2024
Time (UTC) 12:00	Country US	Event Aldeyra Therapeutics Inc Annual Shareholders Meeting Aldeyra Therapeutics Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 1, 2024
Time (UTC) 20:00	Country US	Event Q2 2024 Aldeyra Therapeutics Inc Earnings Release Q2 2024 Aldeyra Therapeutics Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	0	0	0	0	0
Revenue
Total Operating Expense	62.68	56.2195	36.421	63.0743	39.6992
Selling/General/Admin. Expenses, Total	15.3739	11.283	9.98545	12.1547	9.87614
Research & Development	47.3061	44.9365	24.6813	44.3518	29.823
Operating Income	-62.68	-56.2195	-36.421	-63.0743	-39.6992
Interest Income (Expense), Net Non-Operating	0.65535	-1.55674	-1.61198	0.9375	0.80591
Net Income Before Taxes	-62.0246	-57.7763	-38.033	-62.1368	-38.8932
Net Income After Taxes	-62.0246	-57.7763	-37.5537	-60.8268	-38.8932
Net Income Before Extra. Items	-62.0246	-57.7763	-37.5537	-60.8268	-38.8932
Net Income	-62.0246	-57.7763	-37.5537	-60.8268	-38.8932
Income Available to Common Excl. Extra. Items	-62.0246	-57.7763	-37.5537	-60.8268	-38.8932
Income Available to Common Incl. Extra. Items	-62.0246	-57.7763	-37.5537	-60.8268	-38.8932
Diluted Net Income	-62.0246	-57.7763	-37.5537	-60.8268	-38.8932
Diluted Weighted Average Shares	58.4059	54.0421	33.966	27.1118	21.6856
Diluted EPS Excluding Extraordinary Items	-1.06196	-1.0691	-1.10563	-2.24355	-1.7935
Diluted Normalized EPS	-1.06196	-1.0691	-1.05398	-2.00131	-1.7935
Unusual Expense (Income)		0	1.75427	6.56775

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0	0	0	0	0
Total Operating Expense	10.3427	16.8033	13.6968	14.7846	17.7149
Selling/General/Admin. Expenses, Total	3.37975	5.56742	4.73532	3.24494	3.14428
Research & Development	6.96291	11.2359	8.96147	11.5396	14.5707
Operating Income	-10.3427	-16.8033	-13.6968	-14.7846	-17.7149
Interest Income (Expense), Net Non-Operating	1.35566	1.1876	0.79463	0.23132	-0.06602
Net Income Before Taxes	-8.987	-15.6157	-12.9022	-14.5532	-17.781
Net Income After Taxes	-8.987	-15.6157	-12.9022	-14.5532	-17.781
Net Income Before Extra. Items	-8.987	-15.6157	-12.9022	-14.5532	-17.781
Net Income	-8.987	-15.6157	-12.9022	-14.5532	-17.781
Income Available to Common Excl. Extra. Items	-8.987	-15.6157	-12.9022	-14.5532	-17.781
Income Available to Common Incl. Extra. Items	-8.987	-15.6157	-12.9022	-14.5532	-17.781
Diluted Net Income	-8.987	-15.6157	-12.9022	-14.5532	-17.781
Diluted Weighted Average Shares	58.7919	58.7916	58.5646	58.4579	58.3015
Diluted EPS Excluding Extraordinary Items	-0.15286	-0.26561	-0.22031	-0.24895	-0.30498
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.15286	-0.26561	-0.22031	-0.24895	-0.30498
Unusual Expense (Income)

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	181.023	232.753	83.0593	75.1688	94.7693
Cash and Short Term Investments	174.301	229.791	77.8583	73.3644	93.5997
Cash & Equivalents	9.26828	129.426	54.3634	29.0624	45.2303
Short Term Investments	29.8815	0		28.9386	46.2422
Prepaid Expenses	6.72223	2.96178	5.20096	1.80445	1.16959
Total Assets	181.292	233.137	83.3525	75.5183	95.0912
Property/Plant/Equipment, Total - Net	0.26854	0.38435	0.29324	0.34946	0.23523
Other Long Term Assets, Total				0	0.08664
Total Current Liabilities	15.3605	11.7727	12.4095	12.9078	8.47318
Accounts Payable	0.13363	1.0197	0.38164	0.8083	3.05168
Accrued Expenses	14.3152	10.753	8.36808	12.0995	5.4215
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0.91176	0	3.65978		0
Total Liabilities	30.2836	27.4016	23.844	27.436	8.47318
Total Long Term Debt	14.9231	15.5037	11.4345	14.5282	0
Long Term Debt	14.9231	15.5037	11.4345	14.5282	0
Total Equity	151.008	205.736	59.5086	48.0823	86.618
Common Stock	0.05856	0.05808	0.03867	0.02866	0.02624
Additional Paid-In Capital	507.77	500.369	296.386	247.41	225.136
Retained Earnings (Accumulated Deficit)	-356.717	-294.692	-236.916	-199.362	-138.535
Other Equity, Total	-0.10394	0	0	0.00587	-0.00922
Total Liabilities & Shareholders’ Equity	181.292	233.137	83.3525	75.5183	95.0912
Total Common Shares Outstanding	58.5601	58.0812	38.6675	28.6568	26.2444
Cash	135.151	100.365	23.4949	15.3635	2.12718
Other Liabilities, Total	0	0.12523

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	147.21	155.479	168.017	181.023	189.483
Cash and Short Term Investments	143.335	151.676	165.028	174.301	185.329
Cash & Equivalents	46.5314	40.1714	39.7152	9.26828	22.1109
Prepaid Expenses	3.87513	3.80356	2.98912	6.72223	4.15372
Other Current Assets, Total
Total Assets	147.282	155.616	168.219	181.292	189.692
Property/Plant/Equipment, Total - Net	0.07223	0.13723	0.20157	0.26854	0.2086
Total Current Liabilities	21.6173	15.6051	16.0079	15.3605	24.195
Accounts Payable	0.24719	0.27082	0.42969	0.13363	1.30693
Accrued Expenses	7.90902	9.43998	14.6239	14.3152	10.439
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	13.4611	5.89432	0.95433	0.91176	12.4491
Total Liabilities	24.2745	25.7332	30.9756	30.2836	27.4981
Total Long Term Debt	2.65719	10.128	14.9677	14.9231	3.30304
Long Term Debt	2.65719	10.128	14.9677	14.9231	3.30304
Total Equity	123.008	129.883	137.243	151.008	162.194
Common Stock	0.05919	0.0588	0.05879	0.05856	0.05856
Additional Paid-In Capital	512.455	511.144	509.517	507.77	506.235
Retained Earnings (Accumulated Deficit)	-389.506	-381.319	-372.332	-356.717	-343.814
Total Liabilities & Shareholders’ Equity	147.282	155.616	168.219	181.292	189.692
Total Common Shares Outstanding	59.1873	58.8012	58.7916	58.5601	58.5601
Cash	96.8035	111.504	125.313	135.151	106.54
Other Equity, Total	0	0	0	-0.10394	-0.28573
Other Liabilities, Total				0	0
Short Term Investments	0	0	0	29.8815	56.6789
Redeemable Preferred Stock	0		0

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-62.0246	-57.7763	-37.5537	-60.8268	-38.8932
Cash From Operating Activities	-56.6372	-42.5559	-37.4935	-44.9842	-29.8571
Cash From Operating Activities	0.25871	0.26418	0.05622	0.09631	0.071
Non-Cash Items	8.57288	7.5175	9.31286	14.3154	3.96663
Cash Interest Paid	1.33854	1.33708	1.38775	0.23849	0.08896
Changes in Working Capital	-3.44414	7.43869	-8.82955	2.7409	4.99848
Cash From Investing Activities	-29.9545	-0.00781	29.0239	18.4769	-23.3356
Capital Expenditures	-0.01632	-0.00781	0	-0.00953	-0.26297
Other Investing Cash Flow Items, Total	-29.9382	0	29.0239	18.4864	-23.0726
Cash From Financing Activities	1.22009	194.496	41.902	23.5757	80.5268
Financing Cash Flow Items	0.09667	0.06153	0.12697	0.07166	0
Issuance (Retirement) of Stock, Net	1.12343	194.435	41.7751	9.05407	81.9227
Net Change in Cash	-85.3716	151.933	33.4325	-2.93164	27.3341
Issuance (Retirement) of Debt, Net			0	14.45	-1.39583
Deferred Taxes		0	-0.47927	-1.30997

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-15.6157	-62.0246	-49.1225	-34.5692	-16.7883
Cash From Operating Activities	-9.44382	-56.6372	-45.406	-32.8318	-12.8732
Cash From Operating Activities	0.06697	0.25871	0.19206	0.12675	0.06274
Non-Cash Items	4.26297	8.57288	5.6897	3.3879	2.01615
Cash Interest Paid	0.3974	1.33854	0.98183	0.65217	0.3225
Changes in Working Capital	1.84192	-3.44414	-2.1653	-1.7772	1.8362
Cash From Investing Activities	30	-29.9545	-56.9545	-75.9705	-58.0318
Capital Expenditures	0	-0.01632	-0.01632	-0.01632	-0.01632
Cash From Financing Activities	0.05256	1.22009	1.22009	0.02332	0.02332
Financing Cash Flow Items	0.05256	0.09667	0.09667	0.02332	0.02332
Issuance (Retirement) of Stock, Net		1.12343	1.12343	0	0
Net Change in Cash	20.6087	-85.3716	-101.14	-108.779	-70.8817
Other Investing Cash Flow Items, Total	30	-29.9382	-56.9382	-75.9542	-58.0155
Deferred Taxes

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Aldeyra Therapeutics, Inc. Company profile

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). It has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The Company's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses three biological mechanisms of action: reactive aldehyde species (RASP) inhibition, dihydrofolate reductase (DHFR) inhibition, and protein chaperome (CHP) inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation via down-regulation of immune cell activation or proliferation.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 54% to $57.8M. Higher net loss reflects Research and development increase of 98% to $41.4M (expense), General and administrative increase of 15% to $7.7M (expense), General and administrative expenses increase of 8% to $3.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.11 to -$1.07.

Industry:

Bio Therapeutic Drugs

131 Hartwell Avenue
Suite 320
LEXINGTON
MASSACHUSETTS 02421
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024